|
|
|
1-10 employees
View all
|
|
Pharmaceuticals
|
|
Hamilton, BM
|
|
Altamira Therapeutics (former Auris Medical) is dedicated to developing therapeutics that address important unmet medical needs.
The Company is currently active in three areas:
• the development of RNA therapeutics for extrahepatic therapeutic targets (OligoPhore™ / SemaPhore™ platforms; preclinical),
• nasal sprays for protection against airborne viruses and allergens (Bentrio™; commercial) or the treatment of vertigo (AM-125; Phase 2)
• the development of therapeutics for intratympanic treatment of tinnitus or hearing loss (Keyzilen® and Sonsuvi®, Phase 3).
The Company was founded in 2003, under the name Auris Medical, and is headquartered in Hamilton, Bermuda with its main operations in Basel, Switzerland. The shares of Altamira Therapeutics Ltd. trade on the NASDAQ Capital Market under the symbol “CYTO.”
|
Altamira Therapeutics Email Formats | Example Email Formats | Percentage |
---|---|---|
{f}{last} | [email protected] |
75.00%
|
The widely used Altamira Therapeutics email format is {f}{last} (e.g. [email protected]) with 75.00% adoption across the company.
To contact Altamira Therapeutics customer service number in your country click here to find.
Find accurate personal emails, work emails and phone numbers for employees
Accelerate prospecting with instant access to 300M professionals from 30M companies with the right contact details.